Key Players
Competitive Landscape
Supplier competition is increasingly shaped by control of fermentation, formulation support and the ability to maintain useful enzyme activity under commercial feed-processing conditions. Novonesis consolidated the former Feed Enzyme Alliance under one ownership structure in June 2025, bringing research, production, sales and distribution together. BASF remains active through its established enzyme portfolio while evaluating strategic options for the business. Kemin has expanded upstream fermentation capability, while Alltech participates through multi-enzyme nutrition and feeding research.
The route to market is also changing. dsm-firmenich transferred ownership of the Feed Enzyme Alliance activities to Novonesis in 2025 and has separately agreed to divest its remaining Animal Nutrition & Health business to CVC Capital Partners, with completion expected toward the end of 2026 subject to closing conditions. For customers, this makes supplier continuity, technical service, product stability and clear commercial responsibility important when enzyme ownership or distribution structures change.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| June 2025: Novonesis completed its acquisition of dsm-firmenich's share of the Feed Enzyme Alliance. | Customers need a stable route from enzyme development and manufacturing to commercial supply. | Feed-enzyme activities are moving toward integrated biosolutions platforms. | Combine technical service, production and sales support for multi-region feed programs. |
| September 2025: Kemin acquired CJ Youtell Biotech, adding fermentation operations in China. | Enzyme suppliers need dependable manufacturing capacity near major livestock and feed markets. | Application-focused suppliers are adding upstream fermentation capability. | Pair manufacturing scale with species-specific enzyme portfolios and technical support. |
| October 2025: BASF began evaluating strategic options for its feed-enzyme business. | Feed-enzyme portfolios require sustained investment in fermentation, R&D and customer support. | Portfolio owners are reviewing how feed enzymes fit within broader nutrition businesses. | Maintain supply continuity and technical support while strategic ownership decisions develop. |
Taken together, these developments put more weight on manufacturing control, species-specific evidence and customer support. Feed mills are likely to compare not only enzyme activity but also the supplier's ability to deliver consistent product specifications and technical assistance across repeated production cycles.
Who leads the feed enzymes market?
The competitive field includes integrated enzyme manufacturers, application specialists and premix-channel participants. Novonesis controls the former Feed Enzyme Alliance activities, while BASF, Kemin and Alltech participate through different combinations of enzyme portfolio, fermentation capability and application support.
Which suppliers have documented qualification or application capabilities?
BASF provides feed-enzyme products with processing and application support. Kemin combines enzyme formulation with expanded fermentation operations, while Alltech supports multi-enzyme use through product-linked feeding research. Novonesis brings enzyme development, manufacturing, sales and technical service together within its animal biosolutions platform.
Which companies provide manufacturing or fermentation capability?
BASF operates an established feed-enzyme platform. Novonesis combines enzyme development and production with the commercial activities acquired from the Feed Enzyme Alliance. Kemin expanded its fermentation position in 2025 through the acquisition of CJ Youtell Biotech.
What geographic reach is supported by the current company structure?
Novonesis operates feed-enzyme activities across international markets. BASF serves feed customers through an established global enzyme business. Kemin combines China-based fermentation operations with international commercial channels, while Alltech operates across major animal-nutrition markets. dsm-firmenich remains active in animal nutrition during the planned separation of its ANH businesses.
Representative Company Overview
| Company | Positioning | Recent Development |
|---|---|---|
| BASF SE | Established feed-enzyme platform with enzyme brands, technical expertise and an innovation pipeline. | October 2025: BASF began evaluating strategic options for its feed-enzyme business. |
| Novonesis | Integrated animal-biosolutions platform controlling the former Feed Enzyme Alliance research, production, sales and distribution activities. | June 2025: Novonesis completed the acquisition of dsm-firmenich's Feed Enzyme Alliance interest. |
| dsm-firmenich | Animal-nutrition and premix participant after transferring Feed Enzyme Alliance ownership to Novonesis. | February 2026: dsm-firmenich agreed to divest its remaining Animal Nutrition & Health business to CVC Capital Partners, with closing expected at the end of 2026 subject to conditions. |
| Kemin Industries Inc. | Multi-enzyme supplier with expanded upstream fermentation and formulation capability. | September 2025: Kemin acquired CJ Youtell Biotech and its fermentation operations in China. |
| Alltech Inc. | Animal-nutrition company supporting multi-enzyme use with product-linked feeding research. | January 2025: published research reported improved phosphorus digestibility and retention in laying hens receiving Allzyme Spectrum. |
Research Methodology
Company analysis covers the feed-enzyme activities and relevant animal-nutrition roles of the companies profiled in this report. The competitive assessment considers product portfolios, manufacturing and fermentation capability, application support, current corporate developments and geographic participation. Benchmarking is qualitative and no numerical company-share estimates are presented.
